Send us Feedback

Pfizer (PFE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

PFE » Topics » Urology

These excerpts taken from the PFE 10-K filed Feb 27, 2009.

Urology

 

  •  

Viagra remains the leading treatment for erectile dysfunction (ED) and one of the world’s most recognized pharmaceutical brands.

 

  •  

Detrol is the world’s leading product for the treatment of overactive bladder. Detrol LA is an extended-release formulation of this medicine, taken once a day.

 

  •  

Toviaz is Pfizer’s newest offering for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. It is available in two once-daily doses, providing physicians and patients with the ability to optimize treatment through flexible dosing. Toviaz was approved in Europe in April 2007 and in the U.S. in October 2008. It is marketed in 15 European countries and is expected to launch in the U.S. in the first half of 2009.

 

Urology


 







 • 

Viagra remains the leading treatment for erectile dysfunction (ED) and one of the world’s most recognized pharmaceutical brands.

 







 • 

Detrol is the world’s leading product for the treatment of overactive bladder. Detrol LA is an extended-release formulation of this medicine,
taken once a day.

 







 • 

Toviaz is Pfizer’s newest offering for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. It is
available in two once-daily doses, providing physicians and patients with the ability to optimize treatment through flexible dosing. Toviaz was approved in Europe in April 2007 and in the U.S. in October 2008. It is marketed in 15 European
countries and is expected to launch in the U.S. in the first half of 2009.

 

STYLE="position:relative;float:right; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden">

EXCERPTS ON THIS PAGE:

10-K (2 sections)
Feb 27, 2009

RELATED TOPICS for PFE:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki